Fig. 1
From: Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
Descriptive characteristics of patients with osteonecrosis of the jaw induced by immune checkpoint inhibitors based on reports submitted to FAERS database. Note: A, atezolizumab; ECM, endometrial cancer metastatic; F, female; FAERS, the Food and Drug Administration's Adverse Event Reporting System; HL, Hodgkin's lymphoma; HNSC, head and neck squamous cell carcinoma; I, ipilimumab; kg, kilogram; M, male; mg, milligram; MM, malignant melanoma; MRCC, metastatic renal cell carcinoma; N, nivolumab; NSCLC, non-small cell lung cancer; NR, not reported; NA, not applicable; P, pembrolizumab; RC, renal cancer; RCC, renal cell carcinoma; TNBC, triple negative breast cancer